No Data
Mayinglong Pharmaceutical Group (SHSE:600993) Jumps 6.4% This Week, Though Earnings Growth Is Still Tracking Behind Five-year Shareholder Returns
Ma Yinglong: Summary of Ma Yinglong\'s 2024 Annual Report
Ma Yinglong: Ma Yinglong 2024 Annual Report
Ma Yinglong 2024 Annual Report
Ma Yinglong 2024 Annual Report Summary
Mayinglong Pharmaceutical Group (600993.SH): Net income for 2024 is expected to increase by 19.14% year-on-year, proposing a dividend of 6.2 yuan per 10 shares.
On April 2, 2024, Mayinglong Pharmaceutical Group (600993.SH) announced its annual report for 2024, achieving revenue of 3.728 billion yuan, a year-on-year increase of 18.85%; net income attributable to the parent company owners was 0.528 billion yuan, a year-on-year increase of 19.14%; net income attributable to the parent company after deducting non-recurring gains and losses was 0.511 billion yuan, a year-on-year increase of 44.98%. A cash dividend of 6.2 yuan will be distributed for every 10 shares to all shareholders.
Mayinglong Pharmaceutical Group (SHSE:600993) Jumps 4.1% This Week, Though Earnings Growth Is Still Tracking Behind Five-year Shareholder Returns
